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Of the various routes of drug delivery, the oral route is often preferred by the patient. However, peroral 
administration of drugs has disadvantages such as hepatic first-pass metabolism and enzymatic 
degradation within the gastrointestinal tract which constitutes a hindrance to oral administration of 
certain classes of drugs, especially peptides and proteins. Consequently, other absorptive mucosae are 
often considered as potential sites for drug administration. Transmucosal routes of drug delivery (i.e., 
the mucosal linings of the nasal, rectal, vaginal, ocular, and oral cavity) offer distinct advantages over 
peroral administration for systemic drug delivery. These advantages include possible bypass of first-
pass effect, avoidance of presystemic elimination within the GI tract, and, depending on the particular 
drug, better enzymatic flora for drug absorption. However, the mucosa surface as a site for drug delivery 
has limitations as well. Other than the low flux associated with mucosal delivery, a major limitation of the 
transmucosal route of administration is the lack of dosage form retention at the site of absorption. 
Consequently, bioadhesive polymers have extensively been employed in transmucosal drug delivery 
systems. If these materials are then incorporated into pharmaceutical formulations, drug absorption by 
mucosal cells may be enhanced or the drug may be released at the site for an extended period of time.  
This review describes various bio/mucoadhesive polymers used in transmucosal drug delivery. Starting 
with introduction of bioadhesion with theories and mechanism, history, different bioadhesive polymers, 
characteristics of desired bioadhesive polymers, this article then proceeds to cover the various sites 
suitable for mucoadhesive drug delivery system followed by the factors affecting bio/ mucoadhesion. 
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INTRODUCTION 
 
Bioadhesion may be defined as the state in 
which two materials, at least one of which is 
of biological nature, are held together for 
extended periods of time by interfacial forces 
[1]. For drug delivery purposes, the term 
bioadhesion implies attachment of a drug 
carrier system to a specific biological 
location. The biological surface can be 
epithelial tissue or the mucous coat on the 
surface of a tissue. If adhesive attachment is 
to a mucous coat, the phenomenon is 
referred to as mucoadhesion [2]. Mucous 
coat includes the mucosal linings of the 
nasal, rectal, oesophageal, vaginal, ocular, 
and oral cavity.  
 
The idea of bioadhesive drug delivery 
systems was introduced as a new concept to 
the pharmaceutical sciences by the 
pioneering work of several research groups in 
the United States, Japan and Europe in the 
mid-1980s [3-6]. Since then, the idea to 
“stick” dosage forms to the site of application 
and/or drug absorption, respectively, has 
stimulated researchers all over the world. 
Originally, the advantages of bioadhesive 
drug delivery systems were seen in their 
potential (i) to prolong the residence time at 
the site of drug absorption (e.g., to reduce the 
dosing frequency for bioadhesive controlled 
release formulations) and (ii) to intensify 
contact with the underlying mucosal epithelial 
barrier (e.g., to enhance the epithelial 
transport of usually poorly absorbed drugs, 
such as peptides and proteins).  The tight 
and close contact of drug delivery system 
(DDS) with the absorptive mucosa should 
generate a steeper concentration gradient, 
thus increasing the absorption rate [7]. This 
principle, in particular, supported hopes of 
increased bioavailability of peptide drugs. 
 
Later, it was discovered that some 
mucoadhesive polymers can also modulate 
the permeability of epithelial tissues by 
loosening the tight intercellular junctions [8-
9], and that some mucoadhesive polymers 
can also act as inhibitors of proteolytic 
enzymes [10-11].  
 
Over the last 30 years, the market share of 
transmucosal drug delivery systems has 
significantly increased with an estimated 
value of $6.7 million in 2006 [12]. According 
to a recent report published by Kalorama, 
worldwide revenue in this area is expected to 
increase approximately 3.5 % a year to reach 
$7.9bn by 2010 [13]. This growth can be 
related to the ease with which transmucosal 
products can be designed and administered, 
with mucoadhesive polymers playing a vital 
role. 
 
THEORIES AND MECHANISMS OF 
BIOADHESION 
 
Bioadhesion is truly an interfacial 
phenomenon and only differs from 
conventional adhesion in the special 
properties and characteristics of the 
substrate(s) being adhered. The mechanistic 
and structural analyses of the phenomenon 
of bioadhesion have been carefully outlined 
in several comprehensive reviews [14-15]. 
The mechanisms of bioadhesion are often 
classified into chemical and physical 
mechanisms with the electronic theory and 
adsorption theory falling under the former 
mechanism, while wetting, interpenetration or 
diffusion, and fracture theory fall under the 
latter.  
 
DEVELOPMENT OF MUCOADHESIVE 
POLYMERS - A HISTORICAL 
PERSPECTIVE  
 
The development of mucoadhesive polymers 
may be traced back to as far as 1947, when 
gum tragacanth and dental adhesive powders 
were combined to form a vehicle for applying 
penicillin to the oral mucosa. An improvement 
in this system resulted when 
carboxymethylcellulose and petrolatum were 
combined to form the vehicle. The 
development of Orahesive® followed, leading 
to trials of Orabase
®
 in 1959.  
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Table 1: Theories and mechanisms of bioadhesion [16] 
 
 
Orahesive is a mixture of finely ground 
sodium carboxymethylcellulose (SCMC), 
pectin, and gelatin, while Orabase is a blend 
of these in a polymethylene/mineral oil base. 
A further development was the blending of 
sodium carboxymethylcellulose with poly 
(isobutylene) and laminating this mixture onto 
a polyethylene sheet. This system benefited 
from both wet-surface and dry-surface 
adhesion, with the added bonus of being 
protected from physical interference (e.g., 





The polymers identified as exhibiting the best 
adhesion were sodium alginate, sodium 
carboxymethylcellulose, guar gum, 
hydroxyethylcellulose, karya gum, 
methylcellulose, polyethylene glycol (PEG), 
retene and tragacanth. Acrylate polymers 
were soon recognised as useful 
mucoadhesive materials, and the early 1980s 
saw a plethora of patents in which 
hydroxypropylcellulose, or methylcellulose 
and poly (acrylic acid), were blended together 
to form mucoadhesive preparations. By far 
the most widely explored mucoadhesive 
polymers through the 1980s have been poly 
(acrylic acid), hydroxypropylcellulose, and 
sodium carboxymethylcellulose. The work of 
Chen and Cyr [20] together with Park [21] 
and Smart et al. [22], involved the 
Theory Mechanism of bioadhesion Comments 
Electronic 
theory 
Attractive electrostatic forces 
between glycoprotein mucin 
network and the bioadhesive 
material. 
Electrons transfer occurs between the two 
forming a double layer of electric charge at the 
surface 
Wetting theory Ability of bioadhesive polymer to 
spread and develop intimate 
contact with the mucous 
membrane. 
Spreading coefficient of polymers must be 
positive. Contact angle between polymer and 
cells must be near to zero. 
Adsorption 
theory 
Surface force resulting in 
chemical bonding. 
Strong primary force: covalent bonds. Weak 
secondary forces: hydrogen bonds and van der 
Waal’s forces 
Diffusion theory Physical entanglement of mucin 
strands and flexible polymer 
chains. 
For maximum diffusion and best adhesive 
strength, solubility parameters of the 
bioadhesive polymer and the mucus 
glycoproteins must be similar 
Mechanical 
theory 
Adhesion arises from an 
interlocking of liquid adhesive 
into irregularities on the rough 
surface. 
Rough surfaces provide an increased surface 
area available for interaction along with an 
enhanced viscoelastic and plastic dissipation of 
energy during joint failure, which are more 
important in the adhesion process than a 
mechanical effect. 
Fracture theory Analyses the maximum tensile 
stress developed during 
attachment of the transmucosal 
DDS from the mucosal surface 
Does not require physical entanglement of 
bioadhesive polymer chains and mucous 
strands, hence it is appropriate to study the 
bioadhesion of  hard polymers which lack 
flexible chains 
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investigation of a range of polymers of 
varying molecular character. These studies 
appeared to arrive at similar conclusions as 
to the molecular characteristics required for 
mucoadhesion. The properties exhibited by 
such a molecule, described by Peppas and 
Buri [5]
   
may be summarised as follows: (a) 
strong H-bonding groups (-OH; -COOH); (b) 
strong anionic charges; (c) sufficient flexibility 
to penetrate the mucus network or tissue 
crevices; (d) surface tension characteristics 
suitable for wetting mucus/mucosal tissue 
surfaces; and (e) high molecular weight. 
 
CLASSES OF POLYMERS WITH 
BIOADHESIVE PROPERTIES 
 
Hydrophilic polymers  
 
These are water-soluble polymers that swell 
when they come in contact with water and 
eventually undergo complete dissolution. 
Systems coated with these polymers show 
high bioadhesiveness to the mucosa in dry 
state but the bioadhesive nature deteriorates 
as they start dissolving. As a result, their 
bioadhesiveness is short-lived. An example is 




These are three-dimensional polymer 
networks of hydrophilic polymers which are 
cross-linked either by chemical or physical 
bonds. These polymers swell when they 
come in contact with water. The extent of 
swelling depends upon the degree of cross-
linking. Examples are polycarbophil, carbopol 
and polyox [23]. 
 
Co-polymers/Interpolymer complex  
 
A block copolymer is formed when the 
reaction is carried out in a stepwise manner, 
leading to a structure with long sequences or 
blocks of one monomer alternating with long 
sequences of the other. There are also graft 
copolymers, in which entire chains of one 
kind (e.g., polystyrene) are made to grow out 
of the sides of chains of another kind (e.g., 
polybutadiene), resulting in a product that is 
less brittle and more impact-resistant. 
Hydrogen bonding is a major driving force for 
interpolymer interactions. 
 
Thiolated polymers (Thiomers) 
 
These are hydrophilic macromolecules 
exhibiting free thiol groups on the polymeric 
backbone. Based on thiol/disulfide exchange 
reactions and/or a simple oxidation process 
disulfide bonds are formed between such 
polymers and cysteine-rich subdomains of 
mucus glycoproteins building up the mucus 
gel layer. So far, the cationic thiomers, 
chitosan–cysteine, chitosan–thiobutylamidine 
as well as chitosan–thioglycolic acid, and the 
anionic thiomers, poly (acylic acid)–cysteine, 
poly (acrylic acid)–cysteamine, carboxy-
methylcellulose–cysteine and alginate–
cysteine, have been generated. Due to the 
immobilisation of thiol groups on 
mucoadhesive basis polymers, their 
mucoadhesive properties are 2- up to 140-
fold improved [24]. 
 





The majority of pathogens initially infect their 
hosts through mucosal surfaces. Moreover, 
mucosal administration of vaccine avoids the 
use of needles and is thus an attractive 
approach for development of new generation 
vaccines. Current research in vaccine 
development has focused on treatment 
requiring a single administration, since the 
major disadvantage of many currently 
available vaccines is that repeated 
administrations are required. The ability to 
provide controlled release of antigens 
through bioadhesive DDS has given an 
impetus to research in the area of mucosal 
immunisation. Intravaginal immunisation has 
been tried in sheep for the influenza virus 
haemagglutinin [26].  
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Table 2: Rank order of mucoadhesive force for 




Site-targeted drug delivery 
 
Bioadhesive DDS lack specificity, a factor 
that is especially important for orally delivered 
formulations that are targeted to sites within 
the GI tract. This lack of specificity targeting 
results in polymer adhering to the first 
mucosal surface that is encountered leading 
to localised tissue damage. Another issue 
with lack of specificity is that the formulation 
may interact with the loose mucus within the 
GI tract and be coated with this material and 
then pass through the GI tract when it comes 
into close contact with absorbing mucosal 
membrane. Therefore, developing a 
bioadhesive polymer which interacts with a 
particular target is a very attractive potential 
for targeted delivery.  Examples of molecules 
with specific adhesion include lectins, 
bacterial fimbrins and invasions [27].  
 
(a) Bacterial adhesion  
 
Bacterial fimbriae adhere to the binding 
moiety of specific receptors. The 
attractiveness of this approach lies in the 
potential increase in the residence time of the 
drug on the mucus and its receptor-specific 
interaction, similar to those of the plant lectins 
[27]. 
 
(b) Amino acid and Antibodies  
 
Certain amino acid sequences have 
complementary parts on the cell and mucosal 
surfaces and, when attached to 
microparticles, can promote binding to 
specific cell surface glycoproteins. The cell 
surface glycoproteins are altered in the 
presence of disease conditions and these 
altered protein sequences can be targeted by 
complementary amino acid sequences 
attached to the drug delivery device. Due to 
their high specificity, antibody can be a 
rational choice as a polymeric ligand for 
designing site-specific mucoadhesives. This 
approach can be useful for targeting drugs to 




Ion-exchange resins (IER) have been 
extensively studied in the development of 
novel DDSs and other biomedical 
applications. Prolonged gastric retention of 
the drug formulations could improve the 
bioavailability and reduce drug wastage, 
especially for those predominantly absorbed 
from the stomach. Floating dosage forms are 
one of the alternatives designed to prolong 
gastric residence of drugs. Some IER, such 
as cholestyramine, possess bio/muco-
adhesive properties, which might be caused 
by their electrostatic interaction with mucin 
and epithelial cell surface. The use of such 
bioadhesive IER is another attractive 
approach in the development of targeted 
formulations for the GIT. This approach 
would enhance the localized delivery of 
antibiotics, such as tetracycline, to the sites 
of Helicobacter pylori colonisation (fundus), 
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Cell adhesion and bone formation 
 
Cell adhesion to extracellular matrices is 
essential to the development and 
maintenance of bones. Adhesive interactions 
with extracellular matrix components play 
critical roles in osteoblast survival, 
proliferation, differentiation and bone 
formation. Cell adhesion to extracellular 
matrix ligands is primarily mediated by 
integrins, a widely expressed family of 
transmembrane adhesion receptors which 
bind to specific amino acid sequences, such 
as the arginine-glycine-aspartic acid (RGD) 
recognition motif present in many 
extracellular matrix proteins. Over the last 
decade, biomimetic approaches have sought 
to convey biofunctionality to synthetic 
materials by presenting bioadhesive motifs 
derived from extracellular matrix components, 
such as RGD for fibronectin. These 
biomolecular strategies mostly focus on 
immobilising short peptides onto synthetic or 
natural materials to produce biofunctional 
surfaces that bind adhesion receptors and 
promote cell adhesion [30].  
 
Protein and peptide drug delivery 
 
Protein and peptide drugs offer formidable 
challenges for peroral delivery due to their 
relatively large size, enzymatic degradation 
and very low permeability across the 
absorptive epithelial cells. The luminal 
enzymatic degradation of proteins and 
peptides can be effectively minimised by 
direct contact with the absorptive mucosa 
and avoiding exposition to body fluids and 
enzymes. Specific enzyme inhibitors can be 
attached to the surface of bioadhesive 
formulation. Moreover, certain polymers, e.g., 
chitosan have been reported to possess 
permeability enhancing properties. Senel et 
al. observed a six- to seven-fold 
enhancement of permeability by chitosan for 
the bioactive peptide transforming growth 
factor (TGF-β) to which the oral mucosa was 




The replacement of blood vessels is one of 
the most important procedures in 
cardiovascular surgery. The surgical insertion 
of arterial implants with an inner diameter of > 
6 mm is possible with good long-term results 
but venous and arterial implants with a 
narrow lumen of < 4 mm, present current 
limitations. The blood coagulation cascade 
recognizing the synthetic surface occludes 
the blood vessels prosthesis after a short 
period. The lining of analogous endothelial 
cells (ECs) to prosthetic polytetra-
fluoroethylene (PTFE)–grafts has been 
promoted as a method of improving graft 
potency. However, the performance of simple 
coating with extracellular matrix proteins is 
insufficient, in that the cells were washed 
away under perfusion. Thus, the researchers 
covalently coupled a specific cell-adhesion 
molecule to the polymer surface. Only PTFE–
grafts covalently modified with the mentioned 
specific adhesion molecules showed a 
regular cell lining even under perfusion. The 
researchers were able to show that EC 
adhere on formerly inert PTFE surfaces and 
allow a complete lining of the graft. This cell 
monolayer was physiologically active and 
was able to withstand sheer stress in 
perfusion [32]. 
 
CHARACTERISTICS OF AN IDEAL 
MUCOADHESIVE POLYMER [33]  
 
1.  Rapid adherence to mucosa. 
2.  Exhibit strong interaction with the mucin 
epithelial tissue. 
3.  Minimum impact on drug release. 
4.  Good spreadability, wetting, swelling 
and solubility and biodegradability 
properties. 
5. Unaffected by the hydrodynamic 
conditions, food and pH changes.  
6.  Easy to incorporate in various dosage 
forms. 
7.  Possess peel, tensile and shear 
strengths at the bioadhesive range. 
8.  Show bioadhesive properties in both dry 
and liquid state. 
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9.  Demonstrate local enzyme inhibition and 
penetration enhancement properties. 
10.  Demonstrate acceptable shelf life. 
11.  Optimum molecular weight. 
12.  Possess adhesively active groups. 
13.  Possess required spatial conformation. 
14.  Sufficiently cross-linked but not to the 
degree of suppression of bond forming 
groups. 
15.  Possess good viscoelastic properties 
and no breakdown at the mucosa. 
 
FACTORS AFFECTING MUCOADHESION 
IN ORAL CAVITY 
 
Polymer-related factors 
Molecular weight  
 
Generally, the threshold molecular weight 
required for successful bioadhesion is at least 
100,000. For example, polyethylene glycol 
(PEG) with a molecular weight (MW) of 
20,000, has little adhesive character, 
whereas PEG with MW of 200,000 and 
400,000 has improved and superior adhesive 
properties, respectively. Tiwari et al. have 
shown the direct correlation between the 
bioadhesive strength of polyoxyethylene 
polymers and their molecular weights in the 




In general, it has been shown that the 
bioadhesive strength of a polymer increases 
with molecular weights above 100,000. 
Interestingly, adhesiveness of non-linear 
molecular structure follows a quite different 
trend. The adhesiveness of dextran, with a 
very high molecular weight of 19,500,000, is 
similar to that of PEG with a molecular weight 
of 200,000 [2]. The reason for this similarity 
may be that the helical conformation of 
dextran may shield many of the adhesive 
groups, which are primarily responsible for 




Chain flexibility is critical for interpenetration 
and entanglement of mucoasadhesive 
polymers. As water soluble polymers become 
cross-linked, mobility of individual polymer 
chains decrease and thus the effective length 
of the chain that can penetrate into the 
mucous layer decreases, which reduces 
bioadhesive strength. The increased chain 
interpenetration was attributed to the 
increased structural flexibility of the polymer 
upon incorporation of poly (ethylene glycol) 
[35]. 
 
Hydrogen bonding capacity  
 
Park and Robinson found that in order for 
mucoadhesion to occur, the desired polymers 
must have functional groups that are able to 
form hydrogen bonds [36]. The hydrophilic 
functional groups responsible for forming 
hydrogen bonds are the hydroxyl (-OH) and 
carboxylic groups (-COOH). A major reason 
behind the selection of hydrophilic polymers 
for oral transmucosal drug delivery systems 
is the water-rich environment of the oral 
cavity owing to the presence of saliva.  
 
Cross-linking density  
 
The average pore size, the number average 
molecular weight of the cross-linked 
polymers, and the density of cross-linking are 
three important and interrelated structural 
parameters of a polymer network. Therefore, 
it seems reasonable that with increasing 
density of cross-linking, diffusion of water into 
the polymer network occurs at a lower rate 
which, in turn, causes an insufficient swelling 
of the polymer and a decreased rate of 
interpenetration between polymer and mucin. 
Flory
 
has reported this general property of 
polymers, in which the degree of swelling at 
equilibrium has an inverse relationship with 
the degree of cross-linking of a polymer [37]. 
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Charge 
 
In a study of polymer adhesiveness, using a 
cell-culture-fluorescent probe technique, it 
was found that the charge sign of polymer is 
an important element for bioadhesion [3, 38]. 
The strength of mucoadhesion of polymers 
with carboxyl groups was much stronger than 
that of those with neutral groups [39]. Some 
generalizations about the charge of 
bioadhesive polymers have been made 
previously, where nonionic polymers appear 
to undergo a smaller degree of adhesion 
compared to anionic polymers. Peppas and 
Buri have demonstrated that strong anionic 
charge on the polymer is one of the required 
characteristics for mucoadhesion [5]. It has 
been shown that some cationic polymers, 
such as chitosan, exhibit superior 
mucoadhesive properties, especially in a 




At low concentration of the polymer, the 
number of penetrating polymer chains per 
unit volume of the mucus is small and the 
interaction between polymer and mucus is 
unstable. A more concentrated polymer leads 
to longer penetrating chain length and better 
adhesion. Increased concentration of 
bioadhesive polymer, usually from 1.0 - 2.5 
wt%, in principle, increased the binding 
potential. However, for each polymer, there is 
a critical concentration, above which the 
polymer produces an “unperturbed” state due 
to a significantly coiled structure. As a result, 
the accessibility of the solvent to the polymer 
decreases, and chain penetration of the 
polymer is drastically reduced [41]. 
 
 
Hydration (swelling)  
 
A sufficient amount of water appears 
necessary to properly hydrate and expand 
the mucoadhesive network to expose 
available bioadhesive sites for bond 
formation by creating pores, channels or 
macromolecular mesh of sufficient size for 
diffusion of solutes or polymer chains, as well 
as mobilizing the polymer chain for 
interpenetration. Thus, polymer swelling 
permits a mechanical entanglement by 
exposing the bioadhesive sites for hydrogen 
bonding and/or electrostatic interaction 
between the polymer and the mucous 
network. However, a critical degree of 
hydration of the mucoadhesive polymer 
exists where optimum swelling and 






pH can influence the formal charge on the 
surface of mucus as well as certain ionisable 
bioadhesive polymers. Mucus will have a 
different charge density depending on pH due 
to difference in dissociation of functional 
groups on the carbohydrate moiety and the 
amino acids of the polypeptide backbone. For 
example, polycarbophil does not show a 
strong bioadhesive property above pH 5 
because uncharged rather than ionised, 
carboxyl groups react with mucin molecules, 
presumably through numerous hydrogen 
bonds. However, at higher pH, the chains are 
fully expanded due to electrostatic repulsion 
of carboxylate anions [43].  
 
Initial contact time  
 
Contact time between the bioadhesive and 
mucus layer determines the extent of swelling 
and interpenetration of the bioadhesive 
polymer chains. Moreover, bioadhesive 
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Table 3:  Some currently available commercial bioadhesive drug formulations [58] 
 
Brand name Company Bioadhesive polymer Pharmaceutical 
form 
Buccastem Reckitt Benckiser PVP, Xanthum gum 
and locust bean gum 
 Buccal tablet 
Corlan Pellets EllTech Acacia gum Oromucosal pellets 
Suscard Forest HPMC Buccal tablet 
Gaviscon Liquid Reckitt Benckiser Sodium alginate Oral liquid 
Orabase Conva Tech Pectin, gelatin Oral paste 
Corsodyl gel Glaxo Smith Kline HPMC Oromucosal gel 
Nyogel Novartis Carbomer and PVA Eye gel 
Pilogel Alcon Carbomer Eye gel 
Timoptol –LA Merc, Sharpe and Dohme Gellan gum Eye gel- solution 
Aci-jel Janseen-Cilag Tragacanth and 
Acacia 
Vaginal gel 
Crinone Serono Carbomer Vaginal gel 
Gynol-II Janseen-Cilag SCMC and PVP Vaginal gel 
Zidoval 3-M Carbomer Vaginal gel 
 
 
Mucin turnover rate  
 
Estimation of mucin turnover varies widely, 
depending on location and method of 
measurement. Values ranging from a few 
hours to a day have been reported. However, 
residence times of bioadhesives that are 
thought to attach to mucin are typically longer 
than the reported mucin turnover, suggesting 
that the presence of bioadhesive polymer on 
mucin may alter the turnover of this 
biopolymer. The residence time of dosage 
forms is limited by the mucin turnover time, 
which has been calculated to range between 
47 and 270 min in rats and 12 – 24 h in 
humans [45]. 
 
Physiological considerations  
 
In many routes of administration, surface 
mucus is encountered by the bioadhesive 
before it reaches the tissue. The extent of 
interaction between the polymer and the 
mucus depends on mucus viscosity, degree 
of entanglement, and water content. 
Physiological considerations such as texture 
of mucosa, thickness of the mucous layer, its 
turnover time, and other factors, are to be 
considered in designing the dosage forms 
[46].  
 
SITES FOR MUCOADHESIVE DRUG 
DELIVERY SYSTEMS 
 
Buccal cavity  
 
At this site, first-pass metabolism is avoided, 
and the non-keratinized epithelium is 
relatively permeable to drugs. Due to flow of 
saliva and swallowing, materials in the buccal 
cavity have a short residence time and so it is 
one of the most suitable areas for the 
development of bioadhesive devices that 
adhere to the buccal mucosa and remain in 




The vagina is a highly suitable site for 
bioadhesive formulations and it is here that 
the success of the concept can be seen 
convincingly. The bioadhesion increases the 
retention time (up to 72 h) and a smaller 
amount of the active ingredient can be used, 




Ease of access, avoidance of first-pass 
metabolism and a relatively permeable and 
well-vascularised membrane, contribute to 
make the nasal cavity an attractive site for 
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drug delivery. Although the surface area is 
not large (between 150-200 cm
2
), one major 
disadvantage of nasal mucosa is the rapid 
removal of substances by mucociliary action 
(with a residence time half-life of 15 - 30 min) 
[47]. This makes it a prime target for 
bioadhesive formulations to prolong the 





One major problem for drug administration to 
the eye is rapid loss of the drug and or 
vehicle as a result of tear flow, and so it is a 
target for prolonging the residence time by 
bioadhesion. The bioadhesive polymers are 
finding increasing use in ophthalmic 
formulations, but often as viscosity enhancers 
rather than as bioadhesives per se [27].  
 
Gastrointestinal tract  
 
The gastrointestinal tract has been the 
subject of intense study for the use of 
bioadhesive formulations to improve drug 
bioavailability. The problem associated is that 
the polymeric bioadhesive formulations bind 
the intestinal mucus, which is constantly 
turning over and are transported down the 
gut by peristalsis. Another problem is that 
with conventional formulations such as 
tablets, the active ingredient may diffuse 





Tablets or capsules lodging in the 
oesophagus leads to delayed absorption and 
therefore delayed onset of action, as the 
oesophageal epithelial layer is impermeable 
to most drugs. In addition, adhesion at such a 
site may cause problems if localisation of the 
drug or dosage form leads to irritation of the 
mucosa. Development of a DDS that adheres 
to the oesophagus has implications in both 
the protection of the epithelial surface from 
damage caused by reflux and as a vehicle to 
deliver drugs for local action within the 
oesophagus. Bioadhesive dosage forms that 
adhere to the oesophageal mucosa and 
prolong contact have been investigated to 
improve the efficacy of locally acting agents 
[48-49]. 
 
TECHNIQUES FOR EVALUATING 
BIOADHESIVE PROPERTIES 
 
In vitro techniques 
  
Tensile stress measurement 
 
(i) Wilhelmy plate technique: The Wilhelmy 
plate technique is traditionally used for the 
measurement of dynamic contact angles. The 
instrument measures the bioadhesive force 
between mucosal tissue and the dosage form 
[50]. By using the CAHN software system, 
parameters such as fracture strength, 
deformation to failure and work of adhesion 
can be analysed.  
 
(ii) Electromagnetic force transducer (EMFT): 
The EMFT uses a calibrated electromagnet 
to detach a magnetic loaded polymer DDS 
from a tissue sample [51]. It has the unique 
ability to record remotely and simultaneously 
the tensile force information as well as high 
magnification video images of bioadhesive 
interactions at near physiological conditions. 
EMFT measures tissue adhesive forces by 
monitoring the magnetic force required to 
exactly oppose the bioadhesive force.  
 
Shear stress measurement 
 
The shear stress technique measures the 
force that causes a mucoadhesive to slide 
with respect to the mucous layer in a 
direction parallel to their plane of contact [52]. 
Adhesion tests based on the shear stress 
measurement involve two glass slides coated 
with polymer and a film of mucus. Mucus 
forms a thin film between the two polymer 
coated slides, and the test measures the 
force required to separate the two surfaces. 
For this purpose, Mikos and Peppas 
designed the in vitro method of flow chamber 
[53].  
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Rheological approach 
 
The rheological properties of the 
mucoadhesive interface (i.e. of the hydrated 
gel) are influenced by the occurrence of 
interpenetration step in the process of 
bioadhesion. Chain interlocking, 
conformational changes and chemical 
interaction, which occur between bioadhesive 
polymer and mucin chains, produce changes 
in the rheological behaviour of the two 
macromolecular species. The rheological 
studies provide an acceptable in vitro model 
representative of the in vivo behaviour of 
mucoadhesive polymers [54].  
 
Colloidal gold staining method 
 
This technique employs red colloidal gold 
particles, which are stabilized by the 
adsorbed mucin molecule by forming mucin–
gold conjugates [55]. Upon interaction with 
mucin–gold conjugates, bioadhesive 
hydrogels develop a red colour on the 
surface. Thus, the interaction between them 
can easily be quantified, either by the 
measurement of the intensity of the red 
colour on the hydrogel surface or by the 
measurement of the decrease in the 
concentration of the conjugates from the 
absorbance changes at 525 nm. 
 
Viscometeric method  
 
A simple viscometric method was used by 
Hassan and Gallo to quantify mucin–polymer 
bioadhesive bond strength [56]. Viscosities of 
15 %w/v porcine gastric mucin dispersion in 
0.1M HCl (pH 1) or 0.1M acetate buffer (pH 
5.5) were measured with a Brookefield 
viscometer in the absence or presence of 
selected neutral, anionic, and cationic 
polymers.  Viscosity components and the 
forces of bioadhesion were calculated. 
 
Fluorescent probe method 
 
Park and Robinson studied polymer 
interaction with the conjunctival epithelial cell 
membrane using fluorescent probes [3]. The 
study was done in an attempt to understand 
structural requirements for bioadhesion in 
order to design improved bioadhesive 
polymers for oral use. The membrane lipid 
bilayer and membrane proteins were labelled 
with pyrene and fluorescein isothiocyanate, 
respectively. The cells were then mixed with 
candidate bioadhesive, and the changes in 
fluorescence spectra were monitored. This 
gave a direct indication of polymer binding 
and its influence on polymer adhesion. 
  
In vivo techniques 
 
GI transit using radio-opaque technique 
 
It involves the use of radio-opaque markers, 
e.g., barium sulfate, encapsulated in 
bioadhesive DDS to determine the effects of 
bioadhesive polymers on GI transit time. 
Faeces collection (using an automated 
faeces collection machine) and x-ray 
inspection provide a non-invasive method of 
monitoring total GI residence time without 










have been used to study the transit of the 
DDS in the GI tract [57]. 
 
Gamma scintigraphy technique 
 
It is a valuable tool used in the development 
of pharmaceutical dosage forms. With this 
methodology, it is possible to obtain 
information non-invasively. This technique 
gives information in terms of oral dosage 
forms across the different regions of GI tract, 
the time and site of disintegration of dosage 
forms, the site of drug absorption, and also 
the effect of food, disease, and size of the 
dosage form on the in vivo performance of 




Improvements in bioadhesive-based drug 
delivery and, in particular, the delivery of 
novel, highly-effective and mucosa-
compatible polymer, are creating new 
commercial and clinical opportunities for 
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delivering narrow absorption window drugs at 
the target sites to maximise their usefulness. 
Mucoadhesive drug delivery systems are 
being studied from different angles, including 
development of novel mucoadhesives, design 
of the device, mechanisms of mucoadhesion 
and permeation enhancement. With the influx 
of a large number of new drug molecules 
from drug discovery, mucoadhesive drug 
delivery will play an even more important role 
in delivering these molecules. Gains due to 
bioadhesion in the mucosal cavity are less 
obvious, but many potential systems are 
under investigation, and some of these may 
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